Before a cancer therapeutic is selected for clinical development, scientists must fully characterize its mechanism of action, antitumor activity, and dosing parameters in preclinical animal studies. For over 40 years, ALZET® Osmotic Pumps have been used in cancer studies as a reliable and convenient method for continuous dosing of unrestrained lab animals. These small, implantable pumps deliver solutions at controlled rates over prolonged periods, enabling compound levels to be maintained within their therapeutic range to maximize efficacy with lower drug doses and reduce adverse effects and drug toxicity.
A much utilized method of determining the carcinogenic potential of compounds and the therapeutic efficacy of anticancer treatments has been the measurement of cell proliferation levels in tissues of interest. A major challenge in such studies is the ability to maintain a continuous presence of the chosen cell-labeling agent, as variable levels may result in the researcher failing to detect bursts in cell proliferation. The use of ALZET pumps is well documented as a means of delivering cell labeling agents, such as bromodeoxyuridine, at a constant rate, thus ensuring the researcher detects all cell proliferation occurring over the required time period.
The references listed below illustrate the use of ALZET pumps in cancer research for the successful administration of carcinogens, anti-cancer drugs, monoclonal antibodies, enzyme inhibitors, antisense oligonucleotides and more.